Longevity Leaders Logo WhiteRNA Leaders USA Congress Logo White


SCIENTIFIC, CLINICAL AND COMMERCIAL DEVELOPMENT OF RNA THERAPEUTICS AND VACCINES


October 18-19, 2022

Boston, USA

#rnaleaders
@lsxleaders

DOWNLOAD BROCHURE

Created by    LSX

A new paradigm for disease prevention



RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.

With that in mind, we can’t wait to bring the community together, face-to-face, for the RNA Leaders USA Congress.

RNA Leaders World Congress


Meet the speakers from RNA Leaders EU



Douglas Fambrough, CEO, Dicerna Pharmaceuticals

Douglas Fambrough

CEO
Dicerna Pharmaceuticals
Melissa Moore, CSO, Moderna

Melissa Moore

CSO
Moderna
Bill Haney, CEO & Chairman, Skyhawk Therapeutics

Bill Haney

CEO & Chairman
Skyhawk Therapeutics
Sylke Poehling, Senior Vice President and Global Head, Therapeutic Modalities, Roche

Sylke Poehling

Senior Vice President and Global Head
Therapeutic ModalitiesRoche
Shalini Andersson, Chief Scientist, New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

Shalini Andersson

Chief Scientist, New Therapeutic Modalities & Head of Oligonucleotide Discovery
AstraZeneca
Tamar Grossman Global Head of RNA and Targeted Therapeutics, Janssen

Tamar Grossman

Global Head of RNA and Targeted Therapeutics
Janssen
Matthew Wood, Professor of Neuroscience and Deputy Head, Medical Sciences Division, University of Oxford

Matthew Wood

Professor of Neuroscience and Deputy Head, Medical Sciences Division
University of Oxford
David Slack CEO, Cend Therapeutics

David Slack

CEO
Cend Therapeutics
Laura Sepp-Lorenzino, CSO, Intellia Therapeutics

Laura Sepp-Lorenzino

CSO
Intellia Therapeutics
Denis Drygin, CSO, Regulus Therapeutics

Denis Drygin

CSO
Regulus Therapeutics
Angele Maki, SVP, Business Development, ReCode Therapeutics

Angele Maki

SVP, Business Development
ReCode Therapeutics
Sudha Chivukula, Head of RNA Technology, Research & External Innovation, Sanofi Pasteur

Sudha Chivukula

Head of RNA Technology, Research & External Innovation
Sanofi Pasteur
Peter Smith, Co-Founder, President and CEO, Remix Therapeutics

Peter Smith

Co-Founder, President and CEO
Remix Therapeutics
Malgorzata Gonciarz, Associate Vice President, Genetic Medicine, Eli Lilly

Malgorzata Gonciarz

Associate Vice President, Genetic Medicine
Eli Lilly
Huw Nash, COO and CBO, Stoke Therapeutics-1

Huw Nash

COO and CBO
Stoke Therapeutic
Howard Stern, CSO, Korro Bio

Howard Stern

CSO
Korro Bio

DOWNLOAD BROCHURE


Platinum partners


 

Chemgenes logo

 

Precision Nanosystems

 

Gold partners


 

Axolabs 300x

 

Cytiva-1

 

Silver partners


 

Altamira Therapeutics logo

Eclipse Bioinnovations

 

Remix Therapeutics 300x

 

Sisaf Logo

Bronze partners


 

Aptamer group logo

 

Exopharm Logo-1

 

GenScript logo

 

PolyPeptide Group 300x

 

purehoney technologies logo

“We still have work to do, but the future is bright for RNA therapies.”
Lorna Harries, CSO, Senisca

What will you learn?



  • How the RNA field has accelerated in the past two years, including major scientific and clinical developments
  • New advancements in systemic and topical delivery platforms and their applications
  • How computational biology is advancing RNA drug discovery including new tools for target, mechanism and molecule discovery
  • Latest pre-clinical updates spanning mRNA, RNAi, antisense and targeting RNA with small molecules
  • Application of gene therapy and RNA editing approaches

DOWNLOAD BROCHURE

500+ companies actively developing RNA therapeutics

4000+ live clinical trials for RNA therapeutics and vaccines

2 major mRNA vaccine approvals in 2020

3 RNAi therapeutic approvals in the past 4 years

1500+ investors actively looking to fund RNA technology

96 successful fund raises by mid 2021 (vs 101 total in 2020)

More than $1.65bn raised by RNA biotech mid 2021

Millions of lives saved by mRNA vaccines to date

Become a partner



Do you offer products or services to support RNA drug development? The pharma and biotech executives attending RNA Leaders World Congress want to meet you! They are looking for:

    • Delivery platforms
    • Contract research
    • Equipment supply
    • Target discovery tools
    • CDMO and CMC
    • Reagent providers
 
    • RNA editing tools
    • RNA analysis
    • Legal services
DOWNLOAD BROCHURE
Female Founders

Networking, Dialogue And Mentorship For Women In Health And Life Sciences
Members save 25% off all LSX events.

FIND OUT MORE

Subscribe to hear speaker announcements, ticket offers and more